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SUMMARY
Objective: In autoimmune encephalitis the etiologic role of neuronal cell-surface anti-
bodies is clear; patients diagnosed and treated early have better outcomes. Neuronal
antibodies have also been described in patients with pediatric epilepsy without
encephalitis. The aim was to assess whether antibody presence had any effect on long-
term outcomes in these patients.
Methods: Patients (n = 178) were recruited between 1988 and 1992 as part of the
prospective Dutch Study of Epilepsy in Childhood; none received immunotherapy.
Healthy age-matched bone-marrow donors served as controls (n = 112). All sera were
tested for serumN-methyl-D-aspartate receptor (NMDAR), alpha amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptor, leucine rich glioma inactivated 1, contac-
tin associated protein like 2 (CASPR2), contactin-2, glutamic acid decarboxylase, and
voltage gated potassium channel (VGKC)-complex antibodies by standard techniques.
No cerebrospinal fluid (CSF) samples were available. Results were correlated with
clinical data collected over 15 years.
Results: Seventeen patients (9.5%) were positive for VGKC complex (n = 3), NMDAR
(n = 7), CASPR2 (n = 4), and contactin-2 (n = 3), compared to three (3/112; 2.6%)
healthy controls (VGKC complex [n = 1], NMDAR [n = 2]; p = 0.03; Fisher’s exact
test). Titers were relatively low (≤1:100 for cell-surface antibodies), but 8 (47%) of the
17 positive samples bound to the surface of live hippocampal neurons consistent with a
potential pathogenic antibody. Preexisting cognitive impairment was more frequent
in antibody-positive patients (9/17 vs. 33/161; p = 0.01). Fourteen antibody-positive
patients were treated with standard antiepileptic drugs (AEDs); three (17%) became
intractable but this was not different from the 16 (10%) of 161 antibody-negative
patients. In 96 patients with available follow-up samples at 6 and/or 12 months, 6 of 7
positive antibodies had disappeared and, conversely, antibodies had appeared for the
first time in a further 7 patients.
Significance: Neuronal antibodies were found at low levels in 9.5% of patients with
new-onset pediatric epilepsy but did not necessarily persist over time, and the develop-
ment of antibodies de novo in later samples suggests they could be due to a secondary
response to neuronal damage or inflammation. Moreover, as the response to standard
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AEDs and the long-term outcome did not differ from those of antibody-negative
pediatric patients, these findings suggest that routine neuronal antibody testing is
unlikely to be helpful in pediatric epilepsy. However, the higher incidence of preexist-
ing cognitive problems in the antibody-positive group, the CASPR2 and contactin-2
antibodies in 7 of 17 patients, and the binding of 8 of 17 of serum samples to live hip-
pocampal neurons suggest that neuronal antibodies, even if secondary, could con-
tribute to the comorbidities of pediatric epilepsy.
KEY WORDS: Autoantibodies, Pediatric epilepsy, Voltage-gated potassium channel
complex, NMDA receptor.
Key Points
• Low levels of neuronal antibodies are present in ~10%
of patients with pediatric epilepsy at onset but are not
associated with poor long-term outcomes or treatment
intractability
• Antibodies can develop during the course of epilepsy
and are not likely to be the sole cause of epilepsy in
pediatric patients
• However, if associated with clinical features sugges-
tive of autoimmune encephalitis, this “secondary
inflammation” may be immunotherapy responsive as
seen in other antibody-mediated diseases
In adults, autoantibodies to essential neuronal proteins
such as the N-methyl-D-aspartate receptor (NMDAR) and
the voltage gated potassium channel (VGKC)-complex
antigen, leucine rich glioma inactivated 1 (leucine rich
glioma inactivated 1 (LGI1), are now widely recognized
as an important treatable cause of encephalitis.1,2 Patients
present with memory loss, confusion, and seizures in lim-
bic encephalitis with predominantly LGI1 antibodies3,4
and neuropsychiatric features, movement, and autonomic
symptoms in NMDAR-Ab (antibody) encephalitis.5,6
However, the recent characterization of faciobrachial dys-
tonic seizures (FBDS) in patients with LGI1 antibodies
has widened the phenotype to include patients presenting
with seizure predominance.7,8 Recognition of each of
these diseases is important, as they are responsive to
immunotherapies.
In adult and pediatric patients with epilepsy or seizures
without encephalitis, autoantibodies are present in approx-
imately 9–13%.9–12 These patients are more likely to have
been classified as “focal epilepsy of unknown cause” and
show a tendency toward standard antiepileptic drug
(AED) resistance.11,12 However, in these studies, follow-
up was short, and immunologic treatments have been tried
on an empirical basis at a time when the presence of an
antibody was unknown. With increasing interest in the
possible etiologic role of autoantibodies in epilepsy, and
the recognition that early diagnosis and immunotherapy
treatment improves outcome in autoimmune encephalitis,
it is important for the clinician to be able to make
informed decisions regarding which patients to test and
whether the results will affect patient management and
epilepsy outcome.13,14
Here we studied archived samples from patients who had
been sampled within a median 69 days from their first pre-
sentation to the neurologist and followed up for many years.
None of the patients were given immunotherapies and some
were resampled at 6 and 12 months. The results were
compared with age- and sex-matched healthy controls.
Methods
Patient cohort
Children (aged 1 month to 16 years) were enrolled into
the Dutch Study of Epilepsy in Childhood (DSEC) from
four participating centers in The Netherlands between 1988
and 1992. Details of exclusion and inclusion criteria have
been published previously.15,16 Children with a presumed
“acute symptomatic” etiology for their epilepsy (defined as
seizures occurring only during the first week after the onset
of acute neurologic insult, for example, stroke, head
trauma, or central nervous system infection, or concurrently
with an acute systemic metabolic disturbance, for example,
uremia, hyponatremia, or hypoglycemia, or both.17) were
excluded.
Sufficient volumes of serum were available only in 178
children at enrollment (out of the total cohort of 881 patients
who were enrolled and discussed). The median period
between the first seizure and first blood sampling was
69 days (range 0 days to 6.4 years). All of the serum sam-
ples were stored at20°C from collection. A previous study
by the DSEC found no significant differences in sex, etiol-
ogy, or epilepsy syndrome between those children with
available samples and those without.18 Follow-up serum
samples from 96 patients taken at 6 months (n = 30),
12 months (n = 34), and 6 and 12 months (n = 32) after
intake were also available for testing. In addition, 112 age
and sex-matched control samples came from age-matched
sibling donors of bone marrow transplantations (BMTs),
collected between 1985 and 1995 and stored under the same
condition as the patients’ sera.
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Ethics
The DSEC was approved by the ethics committees of all
involved hospitals, and informed consent was obtained in
all cases before enrollment.15,19
Epilepsy classification and definitions
At enrollment, classification of the seizures and epi-
lepsy syndromes was made after discussion by three par-
ticipating pediatric neurologists according to the 1989
International League Against Epilepsy (ILAE) criteria.
This was revised after 2 years and at the end of the most
recent intractability study,20 as some children proved to
have neurologic brain-related morbidities. In view of the
new terminology published in the most recent reorganiza-
tion of the ILAE seizure and epilepsy classification, and
to facilitate interpretation of the new serologic data with
the preexisting clinical data, we have provided definitions
of the terms used in Table 1.
Antibody testing of serum samples
Antibodies to the VGKC complex and to the intracellular
enzyme glutamic acid decarboxylase (GAD) were measured
by radioimmunoassays. To avoid reporting results of low
specificity,21,22 VGKC-complex antibody positivity was set
at >400 pM and GAD positivity at >100 units/ml.11 Cell-
based assays (CBAs) were used to detect antibodies to the
NMDAR, alpha amino-3-hydroxy-5-methyl-4-isoxazole-
propionic acid receptor (AMPAR), LGI1, CASPR2, and
contactin-2. These tests were scored on a visual scale: 0, no
binding; 1, low but specific binding; to 4, strong binding to
all transfected cells by two independent observers as previ-
ously described3,5 and in use for routine diagnostics. All
positive samples were confirmed, and then tested blind by
LW as part of a routine antibody service, with dilutions to
assess the titer; the positives samples were also tested for
binding to the surface of live hippocampal neurons in cul-
ture, prepared from P0 Sprague-Dawley rat pups as
described previously.23,24
Statistical analysis
Descriptive statistics were used to summarize patient
data. Fisher’s exact test was used to compare categorical
data. Data were analyzed using GraphPad Prism 6.0.
Results
Autoantibody testing
Seventeen patients (17/178; 9.5%) were positive for one
antibody (VGKC complex [n = 3]; NMDAR [n = 7],
CASPR2 [n = 4], and contactin-2 [n = 3], compared to 3
[2.6%] of the 112 healthy controls (VGKC complex
[n = 1], NMDAR [n = 2]; p = 0.03; Fisher’s exact test; see
Fig. 1, Table 2). Antibodies to LGI1, AMPAR, or GAD
were not identified in any patients or controls. Although
antibodies binding to the cell-surface antigens were not high
(scoring 1 at dilution 1:20 in 5 and at dilution 1:100 in 9),
eight of these samples bound to the surface of live hip-
pocampal neurons (see Table 2), which suggests potential
clinical relevance.
Clinical features of antibody positive patients
The clinical and paraclinical features, treatment
responses, and outcomes of the antibody-positive patients
are listed in Table 2. All three patients with VGKC com-
plex Abs had cognitive impairment/learning difficulties
(this was not present in the VGKC complex antibody-posi-
tive healthy control). The two patients (cases 1 and 2;
Table 2) with the highest titers (712, 480 pM) had focal
epilepsy that was difficult to treat, needing at least three
AEDs for seizure control initially. Although there were no
antibodies detected to the VGKC-complex-associated pro-
teins, LGI1 and CASPR2 in these samples, both bound to
the surface of hippocampal neurons suggesting potential
clinical relevance.
Three of the seven NMDAR-Ab-positive patients had
learning difficulties before the onset of epilepsy (cases 6–
8), including one severely affected (case 7), and required
Table 1. Definitions of terminology used from the preexisting historical clinical database of theDutch Study of
Epilepsy in Childhood
Terminology Definition
Idiopathic epilepsy (IE) Epileptic syndromes with particular clinical characteristics and specific EEG findings. Unknown origin but presumed
genetic etiology
Remote symptomatic
epilepsy (RSE)
Epilepsies considered the consequence of a known or suspected disorder of the central nervous system resulting in a
static encephalopathy. All children with mental retardation (MR) with epilepsy of unknown cause were classified as RSE
Cryptogenic epilepsy (CE) Epilepsies of unknown origin that do not conform to the criteria for IE or RSE
Terminal remission Interval between the very last seizure and the end of follow-up
Fast response to
medication
6 Months of remission starting within 2 months after initiation of AED
Intractability No remission exceeding 3 months (at least one seizure per 3 months) during a minimum period of 1 year of observation
despite adequate treatment.16 (Arts et al). Early onset intractability: onset of intractability within the first 5 years of
follow-up. Late onset intractability: onset after the first 5 years of follow-up
EEG, electroencephalogram; AED, antiepileptic drug.
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AEDs until the end of follow-up. Three others (cases 4, 5,
and 9) had childhood absence epilepsy with 3-Hz general-
ized spike-wave discharge on electroencephalography
(EEG). Three patients were positive for contactin-2 antibod-
ies (cases 11–13); two were known to be on the autistic
spectrum and one had pharmacoresistant benign epilepsy
with centrotemporal spikes (BECTS) requiring three AEDs
for seizure control. Four patients were positive for CASPR2
antibodies; two (cases 16, 17) had focal epilepsy with peri-
ods of resistance to AEDs.
Comparison of clinical features and long-term outcomes
between antibody-positive and antibody-negative
patients
There were no differences in the sex distribution or age
at onset of epilepsy between antibody-positive and anti-
body-negative patients. Seizure semiology and frequency
also showed no long-term difference, and computed
tomography (CT) and EEG findings were comparable
(Table 3). Overall, however, there was a significantly
higher rate of cognitive impairment/developmental delay
in the antibody-positive patient group (9/17 vs. 33/161;
p = 0.01). These features were all present before the onset
of epilepsy (and hence antibody testing), and included
patients with structural brain abnormalities, mild autism,
and severe global development delay.
At 5-year follow-up, 65% (11/17) of patients in the anti-
body-positive and 78% (125/161) in the antibody negative
group had been seizure-free for >12 months (not signifi-
cant). At final contact, 57% (8/14) of the antibody-positive
patients were taking AEDs compared to 31% (44/140) of
antibody-negative patients (p = 0.07, Table 3), but the rate
of intractability was not different between the two groups
(p = 0.18, Fisher’s exact test).
Testing of follow-up samples
Of the 17 patients who were antibody positive at intake,
further samples at 6 and 12 months were available for anti-
body testing in 7 (Fig. 1H,I). Changes in these short-term
antibody levels (Fig. 1H,I) did not correlate with changes in
seizure frequency or cognitive development (Table 2).
Moreover, 7 (7.7%) of 89 sera from patients who had been
antibody negative (n = 161) were found to be positive at
follow-up (NMDAR-Abs [n = 3], CASPR2-Abs [n = 2],
CASPR2- and NMDAR-Abs [n = 1], and contactin-2-Abs
[n = 1]). Two of these patients became intractable in the
long-term (cases 27 and 64). The antibodies and clinical fea-
tures of these patients are listed in Table S1.
A
B
C
D
E
F
G
H
I
Figure 1.
Autoantibody testing results of the epilepsy and healthy control cohorts. The transfected CASPR2-EGFP tagged transfected HEK cells
(green) are shown (A). Serum from patient 16 binds to the surface of the CASPR2 transfected cells, seen with anti-human IgG labelling
(red, B).The transfected cells (A) and anti-human immunoglobulin (IgG)–labelled cells (B) colocalize indicating a positive result for this
patient (C). The scatter diagrams show the titers and CBA scores of positive tests for each antigen tested at the onset of epilepsy com-
pared with healthy controls; VGKC complex (D), NMDAR (E), CASPR2 (F), and contactin-2 (G). The red dashed line indicates the posi-
tive cut-off used for each assay. The serum samples highlighted by green dots were positive on surface hippocampal staining in vitro.
When available, follow-up samples were tested; four of five NMDAR-Ab positive patients and both VGKC-complex antibody-positive
patients were negative at either 6 or 12 months after intake (H, I). Patient 4 showed an initial reduction in antibody levels then increase
over time. These fluctuating antibody levels did not correlate with developmental regression or seizure activity.
Epilepsia ILAE
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Discussion
Autoantibodies to neuronal surface antigens have been
reported in adults and children with epilepsy and could
indicate an immune basis with obvious management
implications.11–13 However, these studies have been com-
plicated by some use of immunotherapies, and long-term
treatment and outcome data of untreated antibody-positive
patients have not been reported. We were able to test a large,
historical cohort of patients with pediatric epilepsy for neu-
ronal surface antibodies and relate the findings to their epi-
lepsy course over time. The frequency of antibodies were
similar to those reported previously, but were mainly tran-
sient and occurred sporadically; despite lack of
immunotherapies, most autoantibody positive patients had a
good outcome and responded to standard AEDs. The results
suggest, therefore, that routine antibody testing is not neces-
sarily helpful in children with epilepsy and should be
restricted to those with evidence of neuroinflammatory dis-
ease. Nevertheless, the number of patients (n = 11) who
had or developed antibodies to CASPR2 or contactin-2,
proteins that are linked to genetic forms of epilepsy or neu-
rodevelopmental disorders, is an intriguing finding that
deserves further study.
The frequency of antibody positivity in this study cohort
(9.5% compared with 2.6% in controls) was similar to that
published previously for both adult and pediatric epilepsies
(10–16% in patients and <5% in controls). Patients with
acute symptomatic epilepsy had been excluded and, impor-
tantly, the patients did not have any associated clinical fea-
tures of encephalitis (e.g., confusion, memory loss) at the
time of sampling, and none had received immunotherapies.
All cell-based assay–positive samples obtained at onset con-
tained relatively low antibody titers, 8/14 bound to the sur-
face of hippocampal neurons in vitro, and most available
follow-up samples had normalized by 12 months, whereas
antibodies had appeared de novo in seven patients.
Although samples were taken as close to seizure onset as
possible, the median sampling time of 69 days means that
some were taken after the establishment of epilepsy and the
results could, therefore, reflect the consequences of the
epileptogenic process rather than being the primary cause.
Table 3. Comparison of clinical features and outcomes of new onset epilepsy antibody positive and negative patients
Characteristic Antibody positive (n = 17) Antibody negative (n = 161) p-Value
Sex M:F – 9:8 M:F – 72:89
Median age of presentation 5.7 years (range 0.9–15.5) 6.2 (range 0.2–15.8)
Type of epilepsy at enrollment Generalized 9 (53%) Generalized 75 (47%) 0.8
Focal 6 (35%) Focal 82 (51%) 0.3
Other 2 (12%) Other 4 (2%) 0.1
Frequency of seizures
within first 6 months
1–3 6 (35%) 1–3 71 (44%) 0.6
4–25 4 (24%) 4–25 34 (21%) 0.8
Uncountable 7 (41%) Uncountable 56 (35%) 0.6
Etiology at onset Idiopathic 8 (47%) Idiopathic 87 (54%) 0.6
RS incl MR 7 (41%) RS incl MR 43 (27%) 0.3
Cryptogenic 2 (12%) Cryptogenic 31 (19%) 0.7
Preexisting neurologic
signs/abnormal
neurologic examination
3 (17.6%) 17 (10.6%) 0.4
Mental retardation/cognitive
impairment at intake
9 (52.9%) 33 (20.4%) 0.01a
History of febrile seizures
before or after intake
1(5.8%) 32 (19.8%) 0.2
Family history 2 (11.7%) 20 (12.4%) 1
Status epilepticus as
presenting feature
2 (11.7%) 9 (5.6%) 0.2
Abnormal EEG at intake 14 (82%) 126 (78%) 1
CT at intake Normal 8 (47%) Normal 85 (53%) 0.8
Abnormal 4 (24%) Abnormal 29 (18%) 0.5
Not done 5 (29%) Not done 48 (30%) 1
Polytherapy during FU,
range (2–16 years)
4/14 (28.5%) 22/143 (15.4%) 0.3
On AED at final contact,
range (2–16 years)
8/14 (57%) 44/143 (30.7%) 0.07
Intractable at last contact 3 (2 with late onset) (17.6%) 16 (8 with late onset) (9.9%) 0.4
AED, antiepileptic drug; MR, mental retardation; RS, remote symptomatic.
aAnalyzed by Fisher’s exact test.
Epilepsia, 57(5):823–831, 2016
doi: 10.1111/epi.13356
829
CNS Antibodies in Pediatric Epilepsy
Indeed, low-titer antibodies to VGKC complex or
NMDARs have been found in some patients without autoim-
mune neurologic diseases,21,25 and the fact that NMDARs
were found in some children with generalized absence epi-
lepsy makes them unlikely to be pathogenic in these cases.
However, the binding to the surface of live hippocampal
neurons, present in 8 of 17 sera, suggested that the antibodies
could be pathogenic if they reach the brain parenchyma. In
the remaining patients whose antibodies did not bind to the
neurons or to LGI1, the VGKC-complex Abs may be mark-
ers for a neuroinflammatory process rather than for an anti-
body-mediated syndrome, as recently discussed.12,22,26
Surprisingly, therefore, antibodies to CASPR2 or contactin-
2, the other known components of the VGKC complex, were
found in 11 pediatric epilepsy patients (seven at onset, four
during follow-up), but not in controls. This finding draws
attention to the growing area of shared targets and partially
overlapping phenotypes between antibody and genetic forms
of pediatric neurologic disease.12,27
Despite the limitations of a retrospective study with no
access to cerebrospinal fluid (CSF) samples for testing, this
observational study enabled us to investigate the long-term
outcome of antibody positivity in a cohort of patients with
pediatric epilepsy in whom immunotherapies were not used.
Because most patients responded well to standard AEDs
and had a good long-term outcome, this questions the patho-
logic relevance of these low positive antibodies particularly
as, in most cases, the antibodies were transient and disap-
peared by 6 or 12 months follow-up. It seems likely that the
antibodies may have been a secondary response to neuronal
damage before the seizures came under control, rather than
the primary pathogenic agent. Nevertheless, this is not
unprecedented and the development of high levels of
NMDAR-Abs following herpes simplex virus encephalitis
(HSVE) with neurologic deterioration (movement disorder,
behavioral change, seizures, and worsening of brain lesions
on magnetic resonance imaging [MRI]), in patients with no
evidence of reactivation of the herpes simplex virus,28 and
their response to immunotherapy,29 demonstrates that this
“secondary inflammation” may still be pathogenic and
respond to immunotherapy.
From these results, a “mono-immunogenic” cause for
pediatric epilepsy is unlikely, with neuronal antibodies
forming only part of the complex etiologic framework that
includes inflammation, structural abnormalities, and genetic
susceptibility; similar diverse factors may explain the final
outcomes. Future studies investigating predictive biomark-
ers in epilepsy need to include all these factors to indicate
the likely progression of disease and treatment response.
This would be invaluable to both patients and clinicians,30
particularly in drug-resistant refractory cases with associ-
ated comorbidities, commonly seen in pediatric epilepsy.
This group of patients may benefit most from further studies
into antibody presence, antigenic targets, relevance, and
immunotherapy treatment trials.
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